A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Colorectal Cancer (CRC);   Pancreatic Ductal Adenocarcinoma (PDAC);   Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous);   Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor;   Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor;   Advanced or Metastatic Urothelial Carcinoma (UC);   Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions:   Drug: Epacadostat;   Drug: Pembrolizumab;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil;   Drug: Gemcitabine;   Drug: nab-Paclitaxel;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cyclophosphamide;   Drug: Cisplatin
Sponsor:   Incyte Corporation
Recruiting

http://ift.tt/2yThhQX